/
ELDN
$3.88+$0.10 (+2.65%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$291.8M
77M shares
52-week range
$1.35 – $4.60
78% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-3.80
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $11.0K | $182.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$11.0K | −$182.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.8M | $8.1M | $6.1M | $23.7M | $27.1M | $30.3M | $52.0M | $66.3M |
| Operating income | −$14.1M | −$14.2M | −$18.5M | −$36.9M | −$88.4M | −$43.0M | −$70.6M | −$83.3M |
| EBITDA | −$14.0M | −$15.8M | −$16.0M | −$36.7M | −$39.4M | −$116.2M | −$35.4M | −$45.3M |
| Net income | −$14.1M | −$16.0M | −$22.8M | −$34.5M | −$88.0M | −$116.5M | −$36.2M | −$45.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -28.11 | -24.42 | -17.16 | -2.33 | -6.16 | -4.73 | -0.75 | -0.56 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.88 | $-0.88–$-0.88 | 3 |
| 2027 | $0 | $-0.80 | $-0.80–$-0.80 | 2 |
| 2028 | $17M | $-0.80 | $-1.01–$-0.64 | 4 |
| 2029 | $17M | $-0.69 | $-0.69–$-0.69 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.24
Price
$3.88
Implied downside
-94%
Peer comparison
Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
www.eledon.com- Employees
- 33
- IPO / List date
- Sep 17, 2014
- HQ
- IRVINE, CA
Held by traders on TradeandTell
No one on the platform currently holds ELDN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 24,600 | $75.8K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-10-05 | 1-for-18reverse |
Recent trades on TradeandTell
No one on the platform has traded ELDN yet.
